Possibility Of Prescription Research Articles

Analysis of possible cases of acquisitive prescription of public properties presented on example of selected area

The main purpose of this research paper is to analyze the conditions, extent, and reasonable grounds for the acquisitive prescription of public real properties (i.e., those owned by the state treasury and local government units), taking into account the exclusion time for public properties to be subject to the possibility of prescription. The acquisitive prescription of real properties is one of the methods used to regulate the legal status and for the owner to obtain a title of ownership for the property.The analysis was carried out on the example of the city of Krakow. This allowed me to assess the causes and effects as well as the scale of the practical implementation of this legal institution. The final results of the performed research study are proposed actions that should be taken as part of the public property management process aimed at protecting ownership rights by means of stopping the course of acquisitive prescription. The results of the research studies have proven the legitimacy of introducing legal regulations limiting the possibility of the acquisitive prescription of public properties.A comparison of the reasonable grounds and dates of the acquisitive prescription of the real properties in Poland with those in force in other countries (such as the United Kingdom and Germany) was also performed.

APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN

The choice of anticoagulant therapy in patients with atrial fibrillation (AF) and concomitant diseases – coronary heart disease (CHD), including acute coronary syndrome (ACS) in history, peripheral arterial disease (PAD), is discussed in the article. The overall mortality and incidence of myocardial infarction in patients with CHD and AF is higher than in patients with AF without CHD. Patients with AF and PAD compared to patients with AF without PAD have higher risks both stroke and systemic embolism. The prescription of triple antithrombotic therapy is necessary for patients with a combination of AF and CHD who underwent percutaneous coronary interventions (in ACS or elective surgery). The possibility of prescription and duration, the choice of specific drugs and their doses should be determined individually, based on the risks of ischemic events associated with stenting, the risk of ischemic stroke and bleeding. Use of new oral anticoagulants (NOAC) instead of vitamin K antagonists (eg, warfarin), low doses of NOAC, studied in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of clopidogrel as a drug of choice from the P2Y12 inhibitor group, the use of low doses of acetylsalicylic acid (ASA), the routine administration of drugs from the proton pump inhibitor group is recommended to minimize the risk of bleeding. The data of subanalysis of the ARISTOTEL randomized clinical trial, indicating a high profile of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use of ASA, are also presented in the article. The benefits of apixaban over warfarin for reducing the risk of stroke/systemic embolism, total mortality and the risk of bleeding in a subgroup of CHD patients are just as obvious as in the general population of the ARISTOTLE study, and in the subgroup of patients without CHD. Treatment with apixaban, both in the subgroup of patients taking ASA, and a subgroup of patients without ASA, is accompanied by a lower risk of strokes and systemic embolism and a lower incidence of major bleeding. The risk of stroke or systemic embolism was similar in patients with AF and PAD randomized to the apixaban group or to the warfarin group, as well as in patients with AF without PAD. Patients with AF and PAD who received apixaban or warfarin had a similar incidence of major bleeding or clinically significant minor bleeding.

Lawful Prescribing and the Prevention of Diversion

Concern about controlled substance diversion and overview of prescribers by legal and regulatory officials is growing. The article is designed to increase health professionals' awareness of the methods of diversion and to provide guidance on how diversion can be foiled. This paper also should help healthcare practitioners to better understand the regulations governing prescribing of controlled substances. Examples of unlawful prescribing of controlled substances are presented. Some behaviors of persons illegitimately seeking controlled substances from prescribers are described. Strategies to lessen the possibility of prescriptions being altered are discussed. Federal and state laws and regulations pertaining to controlled substances are described.

Science Since Babylon. Derek J. de Solla Price. Yale University Press, New Haven, Conn., 1961. 149 pp. $4.50

The eSCCAN project aims to federate smoking cessation clinics in Europe to share and improve practices. Method: Identification of eSCCAN experts in 26 of the 27 European countries has allowed to organize meetings and internet communication to reach a consensus among the smoking cessation clinics in Europe and to specify their number. Results: The current estimate is that there is about 2500 tobacco cessation clinics in Europe. A minority of them are centers of councelling to stop smoking without the possibility of prescription; a higher number is made of doctors9 offices or paramedics. The vast majority consists of tobacco cessation clinics with several health professionals and all facilities for smoking cessation. Examples of good and bad practices have been described on many topics such as rendez-vous delays, that must be less than 3 weeks for a first appointment. Some definitions have met consensus as the definition of healing, and in particular the period which defines a successful cessation. While waiting to close the debate, the recommendation is to record the cessation at 3, 6 and 12 months, with a particular focus at 6 months. A code and a self-audit in many languages are available on the website for a first evaluation of the activity of the consultations that will enable future improvement. Conclusions: The project provides real rapprochement eSCCAN knowledge to practices for smoking cessation in Europe that support in each country in Europe less than 10% of smokers, but disseminate knowledge and contribute to the assessment for teaching and research.